Kairos Pharma, Ltd. ( (KAPA) ) has provided an update.

On June 29, 2026, Kairos Pharma Ltd. held its 2026 annual meeting of stockholders, where shareholders elected four directors to one-year terms and ratified Weinberg & Company, P.A. as the independent auditor for the fiscal year ending December 31, 2026. The meeting recorded participation from 62.81% of eligible shares, providing strong shareholder backing for the company’s governance and oversight framework.

Stockholders also approved an amendment to the certificate of incorporation authorizing a reverse stock split at a ratio between 1:3 and 1:250, to be implemented at the board’s discretion, signaling potential steps to manage share price and capital structure. In addition, shareholders endorsed executive compensation and expanded the 2023 Equity Incentive Plan by adding 5,000,000 shares and an evergreen provision for automatic 5% annual increases over ten years, reinforcing management incentives and long-term alignment with investor interests.

The most recent analyst rating on (KAPA) stock is a Buy
with a $12.00 price target.
To see the full list of analyst forecasts on Kairos Pharma, Ltd. stock,
see the KAPA Stock Forecast page.